The Paracetamol Market is being driven by Significant use of paracetamol as API in large number of OTC drugs
The Paracetamol Market is expected to grow at a CAGR of 10% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 1074.9 million. In the over-the-counter (OTC) pharmaceutical market, the demand for effective and well-tolerated analgesic drugs, including paracetamol-based formulations, is surging due to ongoing research and development activities. Vendors supplying paracetamol as an active pharmaceutical ingredient (API) hold significant growth potential, given the increasing focus of drug manufacturers on creating novel combinations of paracetamol-based OTC drugs. Compliance with stringent regulatory requirements is crucial for drug approvals, leading to an influx of new paracetamol-based products in the market. These regulatory approvals and product launches serve to boost sales for both drug manufacturers and API vendors, driving up paracetamol purchases during the forecast period.
Get more information on Paracetamol Market by requesting a sample report
The market is segmented based on segments_for_ai.nslist
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
However, the market also witnesses some limitations, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
Market Scope |
|
Report Coverage |
Details |
Page number |
189 |
Base year |
2024 |
Historic period |
2019-2023 |
Forecast period |
2025-2029 |
Growth momentum & CAGR |
Accelerate at a CAGR of 10% |
Market growth 2025-2029 |
USD 1074.9 million |
Market structure |
Fragmented |
YoY growth 2024-2025(%) |
8.8 |
Key countries |
US, Germany, Canada, India, China, UK, France, Japan, Italy, and Brazil |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Find out which segment is leading the market by accessing the free PDF report
The Paracetamol market in France is driven by the availability of brands like GlaxoSmithKline's acetaminophen, which addresses various pain conditions such as migraines, chronic daily migraine, chronic pain, and fever. The regulatory authority has approved forms like Powder, Rectal, Intravenous, and Intravenous Paracetamol for pain management. The elderly population and those suffering from flu, menstrual periods, toothaches, backaches, osteoarthritis, and other health issues benefit from its antipyretic properties. The Migraine Trust emphasizes Paracetamol's role in migraine relief. Longevity and its versatility in treating a wide range of conditions contribute to its popularity in France's healthcare infrastructure.
The Paracetamol market falls under the broader category of Over-The-Counter (OTC) analgesics, which is a significant segment of the global pharmaceuticals market. Key players in this sector include Seqens, among others. The market encompasses entities involved in the research and development (R&D) or manufacturing of essential drugs, such as Paracetamol, used for pain management during conditions like headaches, flu, menstrual periods, and toothaches. The NHS and MOHFW in various regions are major consumers of these drugs. The growth of the global pharmaceuticals market, including Paracetamol, is propelled by demographic shifts, with an aging population leading to a higher demand for essential drugs due to increasing prevalence of age-related health issues. By 2050, nearly a quarter of the US and European populations are projected to be over 60 years old, necessitating increased production and availability of essential drugs.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted